ProSomnus® Sleep Technologies Announces
Launch of the ProSomnus® [CA] LP Continuous Advancement Sleep Device
ProSomnus is the Leader in Precision Oral Appliance Therapy for Obstructive Sleep Apnea (OSA)
San Francisco, CA, November 4, 2019 – ProSomnus Sleep Technologies is pleased to announce the official launch of the ProSomnus [CA] LP Continuous Advancement Sleep Apnea Device. ProSomnus [CA] LP is the only low-profile Continuous Advancement OAT Medical Device for OSA. In addition to the ProSomnus platform advantages such as fewer side effects, biocompatible hygienic material, impression-free digital replacements and device customizations, [CA] LP uniquely offers clinicians precision Continuous Advancement without compromising patient comfort. ProSomnus [CA] LP utilizes proprietary technologies to resolve the archform asymmetries, manufacturing variances, bulkiness and other device design limitations of traditional dorsal style Continuous Advancement devices.
“We love the precision fit of the ProSomnus [CA] LP, which means less time fussing during delivery,” stated Drs. Jeffrey S. Rein, DDS and Neal Seltzer, DMD of Long Island Dental Sleep Medicine. “The small profile is comfortable for patients and allows less protrusion for an effective, therapeutic benefit for this lifetime therapy.”
Patented, FDA cleared and designed for the AADSM effective OAT definition, ProSomnus [CA] LP has 34% overall lower profile and ensures more flex for easy delivery. With natural anatomical scalloping, the ProSomnus [CA] LP is optimized for greater tongue space, measuring 38% less bulk for lip closure and 29% less bulk for buccal comfort. This device offers the smallest profile of all Continuous Advancement devices and presents 12.0mm Advancement Range and 3.0mm Lateral Freedom of Movement. Engineered for comfort and to reduce side effects, the ProSomnus [CA] LP is biocompatible and made from hygienic material.
“Adherence is of paramount importance to Dental Sleep Medicine providers and prescribing sleep physicians. Studies show that many patients cannot tolerate CPAP, and Oral Appliance Therapy devices can be bulky and unreliable, particularly those with advancement straps or adjustment screws,” noted Len Liptak, CEO of ProSomnus. “Designed with these insights in mind, new ProSomnus CA [LP] is 34% smaller than predicate devices and offers precision adjustability, all with the goal of helping clinicians create more effective, efficient and comfortable treatment experiences for patients.”
Here’s what leading Dental Sleep Medicine clinicians have to say about ProSomnus [CA] LP:
“ProSomnus has truly improved Continuous Advancement devices for OAT. Their ‘new’ [CA] LP is a breakthrough in design and features, offering the smallest profile of any Continuous Advancement device. Satisfying the doctor and patient needs with biocompatible material, durability, ease of use, less protrusion and great effectiveness. ProSomnus [CA] LP means better patient compliance and better treatment results,” stated John A. Carollo, DMD, D.ABDSM of Dental Sleep Medicine of NJ.
“ProSomnus delivers a consistently reliable product. The new ProSomnus [CA] LP with its sleek design, slim interface and angled adjustment mechanism make it easy and comfortable for the patient to wear. This translates into greater compliance and ultimately a healthier treated patient. It’s a great appliance if you’re looking for a smaller, yet durable device,” stated Kevin R. Wallace, DMD, D.ABDSM of Midwest Dental Sleep Center.
ProSomnus Sleep Technologies will be showcasing the new ProSomnus [CA] LP device at the upcoming AADSM Mastery programs in Oak Brook, IL, November 8-10, 2019, respectively. 1-844-53SLEEP | 5860 West Las Positas Blvd., Suite 25, Pleasanton, CA 94588 | ProSomnus.com
About ProSomnus Sleep Technologies
ProSomnus® Sleep Technologies designs, manufactures and markets FDA Cleared Class II Medical Devices for the treatment of Obstructive Sleep Apnea. Diagnosed by Medical Doctors and provided by Dentists, ProSomnus Devices are the first, precision oral appliance therapy devices designed to enhance compliance, mitigate side effects and enable providers to achieve excellent patient experiences and outcomes. They have been used to treat thousands of patients, with clinical performance that has been validated in numerous studies.
Media Contact : Heather Whalen, VP Marketing firstname.lastname@example.org